clinical trial · NCT07608666
Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase1·not yet recruiting·n = 17
MyelofibrosisTQ05105 tabletsRabeprazole sodium enteric-coated tablets
brief summary
Primary objective: To evaluate the effect of rabeprazole on the primary pharmacokinetics of TQ05105 tablets. Secondary objective: To assess the safety and tolerability of single oral administration of TQ05105 tablets alone and in combination with rabeprazole in healthy study participants. To evaluate the effect of rabeprazole on the secondary PK parameters of TQ05105 and the pharmacokinetics of its active metabolite TQ12550.
started
Jul 1, 2026
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Jul 13, 2026
official title
A Single-center, Open-label, Single-dose, Fixed-dose Regimen, Self-controlled Phase I Clinical Trial to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the pH-dependent Pharmacokinetics of TQ05105 Tablets
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol